GlaxoSmithKline (GSK) has completed the sale of its thrombosis brands, Arixtra and Fraxiparine, to South Africa's Aspen Pharmacare (APNHF) for £700M following regulatory authorization of the transaction.
The sale fits in with GSK's strategy of focusing on growth products and the delivery of its pipeline. (PR) (Previous)
Merck (MRK) agrees to sell a Dutch active pharmaceutical ingredient business and a portfolio of 11 drug brands to South Africa's Aspen Pharmacare (APNHF.PK) for $1B. The deal follows news last week that Aspen is acquiring GlaxoSmithKline's Arixtra and Fraxiparine/Fraxodi brands of thrombosis drugs in a transaction that could be worth $1B. (PR)
More on GSK (GSK -0.3%) / Aspen (APNHF.PK) deal: Reuters speculates that GSK's sale of its thrombosis drug brands Arixtra and Fraxiparine to Aspen could be worth £700M, or twice this year's anticipated sales of around £350M. That would be down from £420M in 2013 and £510M in 2011. Around 1,000 GSK workers, mostly in France, would transfer to Aspen. News of the prospective sale prompted speculation that GSK may look to offload other older drugs.
GlaxoSmithKline (GSK) has received an offer from South Africa's Aspen Pharmacare (APNHF.PK) for its thrombosis drug brands Arixtra and Fraxiparine (excluding China, India and Pakistan), and the related manufacturing site. GSK said any sale would fit in with its strategy of focusing on growth products and the delivery of its pipeline. (PR)
GlaxoSmithKline (GSK) agrees to sell 25 older drugs marketed in Australia to South Africa's Aspen Pharmacare for £172M as GSK continues its divestment of non-core treatments. The deal follows three divestitures within GSK's non-prescription division over the past several months.
South Africa's Aspen Pharmacare (APNHF.PK) agrees to buy the drugmaking arm of Australia's Sigma Pharmaceuticals for $804M in cash, gaining control of around 25% of Australia's generic drugs market. Sigma hopes to put the deal to a shareholder vote at the end of October.